Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ:323990)

South Korea flag South Korea · Delayed Price · Currency is KRW
9,490.00
-390.00 (-3.95%)
At close: Feb 6, 2026
-6.04%
Market Cap220.71B -12.3%
Revenue (ttm)n/a +13,737.3%
Net Incomen/a
EPSn/a
Shares Out23.26M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume229,032
Average Volume322,215
Open9,800.00
Previous Close9,880.00
Day's Range9,230.00 - 9,800.00
52-Week Range6,970.00 - 12,670.00
Beta0.97
RSI46.19
Earnings DateNov 11, 2025

About Vaxcell-Bio Therapeutics

Vaxcell-Bio Therapeutics Co., Ltd. develops and anticancer immunotherapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 323990
Full Company Profile

Financial Performance

In 2024, Vaxcell-Bio Therapeutics's revenue was 1.90 billion, an increase of 13737.28% compared to the previous year's 13.72 million. Losses were -10.62 billion, 3.40% more than in 2023.

Financial Statements